Erin McEvoy

In April 2023, two cannabis testing laboratories launched a certification program to promote higher standards for cannabis testing laboratories across the country.

Bipartisan legislation was recently reintroduced to remove barriers preventing veterans accessing medical cannabis as recommended by health care providers at the VA.

A pharmaceutical company, Vantage Hemp Co., announced it recently submitted two Drug Master Files (DMFs) to the Food and Drug Administration.

One recently published study suggests that a cannabis sublingual spray may be beneficial in the treatment of type 2 diabetes.

What is Cherissa Jackson, RN most excited about as the medical track program chair for Cannabis Science Conference?

A recently published case study documents one chronic pain patient’s reduction of prescribed pain medication after being referred to a medical cannabis registry. Prescribed cannabis-based medicinal products (CBMPs) have been legal in the UK since 2018.

Oregon Psilocybin Services (OPS) issued first psilocybin manufacturer license since accepting applications earlier this year.

Read an interview from Pharmaceutical Technology Europe exploring how the European bio/pharma industry’s high regulatory standards and GMP requirements are set to position the region as a frontrunner for pharmaceutical grade manufacturing of cannabis-based medicines.

Initial findings from a recent study suggested that cannabidiol (CBD) derivatives made naloxone treatment more effective, even against the opioid fentanyl.

The study will examine consumption and health of the participants after purchasing selected cannabis products from controlled cultivation under regulated conditions.

In late March, the Wine & Spirits Wholesalers of America submitted a letter to congressional leadership expressing its support for cannabis legalization that uses regulatory frameworks similar to those of the alcohol industry.

The Food and Drug Administration (FDA) will hold an educational webinar on cannabis and cannabis-derived products for healthcare practitioners in late March.

Health and safety notices were issued in two states due to concerns about contamination exposure.

In late March the Pennsylvania Commonwealth Court ruled that workers’ compensation must cover the cost of medical cannabis for treatment of injuries suffered on the job.

Hear a Noid Factoid from our latest podcast guest!

The owner and two biologists at Royal Queen Seeds recently presented their F1 hybrid process and strains in Barcelona, Spain.

A pioneer in global cannabis research, Professor Raphael Mechoulam died March 9th, 2023 in Israel at the age of 92.

A pioneer in global cannabis research, Professor Raphael Mechoulam died March 9th, 2023 in Israel at the age of 92.

The 2023 Portland show will include four tracks–analytical science, medical cannabis, cultivation, psychedelics–plus a discussion on medical cannabis for veterans, and more!

In early March 2023, the US Justice Department launched an online application for individuals who were pardoned for simple possession of cannabis under President Biden's October 6, 2022 proclamation. Applicants can now receive a certificate of proof of their pardon.

If passed into law, SB 1466 would reduce cost of renewing a medical cannabis card in Arizona, among other changes. The bill passed the senate with bipartisan approval 24 to 6 on March 2, 2023 (1).

A civil lawsuit filed in Arkansas by a medical cannabis patient alleges that three cannabis growers and one testing laboratory inflated the amount of tetrahydrocannabinol (THC) in numerous cannabis products.

In early 2023, Yale School of Medicine announced the foundation of a new center for cannabis research. The center’s inaugural director recently provided commentary on the goals and direction of the research.

While many psychedelics are classified as Schedule I drugs under the federal Controlled Substances Act, the recent resurgence of interest in their potential therapeutic benefits means the landscape around psychedelics is rapidly evolving. New laws and regulations are proposed and passed at the local, state, and federal levels. Research continues to increase as well, contributing to the questions and perspectives surrounding the various uses of psychedelics. In this interview, Dustin Robinson, Esq., CPA, Managing Principal of Iter Investments; Co-Founder of Nucleus; Founding Partner of Mr. Cannabis Law; and Co-Founder of Mr. Psychedelic Law explains how he navigates the complex legal landscape of psychedelics, the surprises and challenges he encounters, and how he envisions psychedelics in the United States in the near future.

Recently, the University of Oxford began an international study to examine the potential therapeutic benefits of cannabidiol (CBD) in treating psychosis or psychotic symptoms.

On February 13, 2023, the US Drug Enforcement Administration (DEA) declared in a letter that the cannabinoids delta-8 and -9 THCO are both considered controlled substances due to their chemical structures.

The House and Senate introduced a revised bill to mandate Veterans Affairs (VA) to conduct research on the effects of medical cannabis on veterans with post-traumatic stress disorder (PTSD) and chronic pain.

A major focus area when it comes to medical cannabis is patient and healthcare education, or rather the lack of that education and rampant misinformation. When Megan Mbengue, BSN, RN, CHPN, saw this gap in educational resources firsthand for people who are looking to use cannabis as a treatment, she decided to launch Trusted Canna Nurse with a mission to break stigma through education. Voted a Cannabis Nurse Entrepreneur of the Year by Cannabis Nurses Networks in 2022, Mbengue and her team offer cannabinoid education, consultations, and a line of products for the spectrum of chronic illnesses. In this interview, Mbengue shares how and why she provides guidance as a cannabis nurse for symptoms of conditions such as ADHD, cancer, autism, chronic pain, and more. She also describes the difficulties presented by the lingering stigma of cannabis and explains her hopes for the role of nurses in medical cannabis.

Cannabidiol (CBD) was recently studied in Mexico as a treatment for traumatic brain injury and Parkinson’s Disease.

Next month the University of Connecticut (UConn) will hold a two-day cannabis symposium covering a wide variety of topics.